MTEM Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases...

Stats
Dagens volum	68 803.00
Gjennomsnittsvolum	64 717.00
Markedsverdi	9.16M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-0.780 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.0330 (1.94%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Biotech Target N V	Buy	250 000	Common Stock
2024-04-02	Biotech Target N V	Buy	769 334	Common Warrants (right to buy)
2024-04-02	Biotech Target N V	Buy	134 667	Prefunded Warrants (right to buy)
2024-04-02	Lalande Kevin M.	Buy	1 154 154	Warrants (Right to Buy)
2024-04-02	Lalande Kevin M.	Buy	402 077	Pre-Funded Warrants (Right to Buy)

INSIDER POWER
99.93
Last 98 transactions
Buy: 16 322 736 \| Sell: 222 785

Volum Korrelasjon

Lang: 0.01 (neutral)

Kort: -0.59 (weak negative)

Signal:(58.538) Neutral

Molecular Templates Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Molecular Templates Inc Korrelasjon - Valuta/Råvare

-0.41
( neutral )

-0.30
( neutral )

0.00
( neutral )

-0.30
( neutral )

-0.03
( neutral )

-0.19
( neutral )

Molecular Templates Inc Økonomi

Annual	2023
Omsetning:	$57.31M
Bruttogevinst:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2023
Omsetning:	$57.31M
Bruttogevinst:	$50.40M (87.94 %)
EPS:	$-1.800

FY	2022
Omsetning:	$19.75M
Bruttogevinst:	$11.95M (60.51 %)
EPS:	$-24.69

FY	2021
Omsetning:	$38.70M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$1.690

Financial Reports:

No articles found.

Molecular Templates Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.